Rapid Micro Biosystems (RPID) Q4 2025 earnings review
Massive Q4 Volume Masks Messy Margin Reversal
Rapid Micro Biosystems delivered a blowout Q4 top line, with revenue accelerating 37% YoY to $11.3M on the back of a record 16 system placements (driven by a massive Amgen order). However, the underlying earnings quality took a hit. GAAP gross margin, which had been tracking positively all year, suffered a Reversing trend to -3% due to a $1.1M write-off of unusable inventory and warranty costs. Management's 2026 guidance is highly ambitious, forecasting up to $41M in revenue and a massive structural leap to ~20% gross margins. While the commercial traction with top-20 biopharma is undeniable, the extreme lumpiness of orders and unproven margin trajectory make 2026 a 'show-me' execution year.
🐂 Bull Case
The Q4 multi-system order from Amgen and the Q1 2026 follow-on from Samsung Biologics prove that top-tier CDMOs and biopharma companies are transitioning from single-site testing to standardizing on Growth Direct across their global manufacturing networks.
Management's guidance of ~20% gross margin for FY26 implies a major structural breakthrough. If achieved, driven by manufacturing efficiencies and the MilliporeSigma supply agreement, the path to profitability becomes much clearer.
🐻 Bear Case
Placements are highly concentrated. Q4 accounted for 16 of the 28 systems placed in all of FY25 (57%). This reliance on massive, binary year-end capital flushes creates extreme quarter-to-quarter revenue volatility.
Just when gross margins seemed stable, a $1.1M hit for unusable inventory and related warranty expenses dragged Q4 GAAP margin back to -3%. This raises concerns about manufacturing quality control and inventory management.
⚖️ Verdict: ⚪
Neutral. The commercial momentum with Amgen and Samsung is genuinely impressive and supports the top-line story. However, a surprise margin reversal and ongoing $47M annual cash burn require investors to underwrite a flawless operational execution in 2026 to hit the 20% margin target.
Key Themes
Accelerating Enterprise-Wide Deployments
The narrative has definitively shifted from landing initial pilots to securing enterprise-wide rollouts. After placing only 12 systems combined in the first three quarters of 2025, Q4 saw an Accelerating 16 placements. The Q4 Amgen multi-system order and the subsequent Samsung Biologics Q1 2026 follow-on indicate that major players are finally pulling the trigger on global standardization for automated microbial quality control.
Margin Reversal Breaks the Streak
A major red flag: Gross margin Reversing to -3% in Q4 from +9% in Q3 breaks a multi-quarter streak of positive margins. Management cited a $1.1M write-off of unusable inventory and related warranty expenses. Even adding this back, the Non-GAAP adjusted margin of 7% represents sequential deceleration from Q3's 9%, despite Q4 benefiting from massive volume leverage (78% higher product revenue). This suggests underlying unit economics remain fragile.
MilliporeSigma Partnership Nearing Financial Impact
The strategic collaboration with Merck KGaA (MilliporeSigma) is transitioning from planning to execution. Beyond serving as a global commercial channel to accelerate placements, the pending product supply agreement is a critical catalyst for the targeted 2026 gross margin expansion, aimed at lowering consumable component costs.
Cash Burn Remains Stubbornly High
Despite revenue growing 20% in FY25, Net Loss remained completely Stable at $47.1M (vs $46.9M in FY24). The company ended the year with $39M in cash and investments, having tapped $18.9M from a new Trinity Capital debt facility. At the current burn rate, the company has roughly 12 months of runway without drawing the remaining $25M debt capacity or improving cash flow dramatically.
U.S. Pharma Onshoring Tailwind
Management continues to position the company to benefit from the >$150 billion investment wave in U.S.-based pharmaceutical manufacturing. New state-of-the-art facilities in high-cost labor environments are prime targets for automated quality control systems to minimize headcount and compliance risks.
Other KPIs
Decelerating sharply, down 34% YoY from $3.0 million in 24Q4. Management attributes this volatility strictly to the timing of validation activities. The company only completed 3 validations in Q4, compared to 9 in Q1 and 4 in Q3. This highlights that service revenue is heavily tied to the unpredictable installation timelines of customer sites.
Stable and compounding. Recurring revenue (consumables and service contracts) grew 15% YoY for the full year, representing 53% of total revenue. As the installed base grows (now at 190 cumulative placements), this higher-margin annuity stream acts as a crucial buffer against lumpy hardware sales.
Guidance
Stable. The midpoint of $39.0M implies 16% YoY growth, a slight deceleration from the 20% growth achieved in FY25. This likely reflects a realistic expectation of hardware sales timing, relying heavily on the MilliporeSigma commercial engine to backfill the pipeline after the massive Amgen/Samsung drain.
Accelerating. This is the most aggressive and important metric in the release. Jumping from 3% in FY25 to ~20% in FY26 requires flawless supply chain execution, the immediate realization of MilliporeSigma supply agreement benefits, and an end to inventory write-offs.
Accelerating. Up from 28 placements in FY25. The midpoint of 34 implies a healthy 21% volume growth, driven by enterprise standardization trends and early contributions from the new commercial channels.
Key Questions
Inventory and Warranty Write-off Autopsy
Can you provide specific details on the $1.1M inventory and warranty write-off in Q4? Was this isolated to a specific component batch, or does it point to a structural design issue that required retrofitting deployed systems?
Bridging to 20% Margin
Walking from a 3% FY25 gross margin (and negative in Q4) to ~20% for FY26 is a massive leap. Can you break down the specific components of this 1700 bps bridge? How much is pure volume leverage vs. structural cost-downs from the MilliporeSigma supply agreement?
Cash Runway and Debt Capacity
With $39M in cash and a ~$47M annual Net Loss burn rate, how does management view the liquidity runway? Are the milestones for the remaining $25M Trinity Capital tranches strictly tied to commercial placement volumes, or are there margin/cash flow covenants?
Service Revenue Stabilization
Given the 34% drop in Q4 service revenue due to validation timing, what changes are being implemented to smooth out the validation pipeline and prevent such severe quarter-to-quarter swings in the service business?